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PharmacokineticsAbstract A simple, precise, selective and fast ultra-high performance liquid chromatography
(UHPLC-UV) method has been developed and validated for the simultaneous determination of a
lipid regulating agent fenoﬁbrate and its metabolite fenoﬁbric acid in rat plasma. The chromato-
graphic separation was carried out on a reversed-phase Acquity BEH C18 column using metha-
nol–water (65:35, v/v) as the mobile phase. The isocratic ﬂow was 0.3 ml/min with rapid run
time of 2.5 min and UV detection was at 284 nm. The method was validated over a concentration
range of 100–10000 ng/ml (r2P 0.9993). The selectivity, speciﬁcity, recovery, accuracy and preci-
sion were validated for determination of fenoﬁbrate/fenoﬁbric acid in rat plasma. The lower limits
of detection and quantitation of the method were 30 and 90 ng/ml for fenoﬁbrate and 40 and
100 ng/ml for fenoﬁbric acid, respectively. The within and between-day coefﬁcients of variation
were less than 5%. The validated method has been successfully applied to measure the plasmax-2457,
d fenofi-
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jsps.2016.05.008concentrations in pharmacokinetics study of fenoﬁbrate in an animal model to illustrate the scope
and application of the method.
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Fenoﬁbrate (FF) is a member of ﬁbrate class with lipid-
regulating action commonly referred to as ﬁbric acid derivative.
It is chemically known as (2-[4-(4-chlorobenzoyl) phenoxy]-2-
methylpropionic acid 1-methylethyl ester) (Fig. 1A). It is almost
white crystalline powder, which is stable under ordinary condi-
tions with melting point 79–82. It is virtually water insoluble
(<0.3 lg/ml) but slightly soluble in alcohol and has relatively
high octanol/water partition coefﬁcient (logP 4.6) (Mohsin,
2012). FF is mainly used to reduce the amounts of low-density
lipoprotein (LDL)-cholesterol, total cholesterol, triglyceride
and apolipoprotein B, and increase the amounts of high-
density lipoprotein (HDL)-cholesterol in the blood (Najib,
2002). Fenoﬁbrate is a prodrug which is converted rapidly after
oral administration through the hydrolysis of the ester bond to
fenoﬁbric acid.
Fenoﬁbric acid (FA) is the active metabolite of fenoﬁbrate
(FF) and chemically known as (2-[40-(p-chlorobenzoyl)
phenoxy]-2-methylpropionic acid) (Fig. 1B), with mechanism
of action that activate peroxisome proliferator activated recep-
tor alpha (PPAR alpha). By this mechanism the lipolysis and
elimination of triglyceride-rich particles from plasma is
increased. Fenoﬁbric acid is used along with a proper diet to
help lower ‘‘bad” cholesterol and fats (such as LDL, triglyc-
erides) and raise ‘‘good” cholesterol (HDL) in the blood. Clin-
ically lowering triglycerides in people with very high
triglyceride blood levels may decrease the risk of pancreas dis-
ease (pancreatitis) (Mohsin et al., 2009; Ratanabanangkoon
et al., 2008).
In the current global health care market, FF has been
remained as a blockbuster drug to satisfy the high demand
(Weng et al., 2014). It is always preferable to conduct clinical
research by characterizing nonhuman (animal models) pharma-
cokinetics for the drugs to assess and design the dose regimen
for clinical trials. Many methods for analysis of FF in pharma-
ceutical formulations and/or in biological ﬂuids have been
reported in the literature including liquid chromatographyfenoﬁbrate (MW: 360.8) and
cid (MW: 318.75).
. et al. Development and validation of b
rat plasma: Application to pharma(LC) (Masnatta et al., 1996; Wang et al., 2012), LC–Mass Spec-
trometry (MS) (Wabaidur, 2013), UPLC–electrospray ioniza-
tion mass spectrometry (Bhavesh and Shah, 2009), and
derivative spectrophotometry (Rozet et al., 2006; Trivedi
et al., 2005). Only a very few HPLC methods have been
reported in the literature and they were very lengthy and
tedious for the estimation of FF and FA present in biological
ﬂuids (Cho and Park, 2014; Fei et al., 2013; Streel et al.,
2000). Hence the author has made an attempt to develop a sim-
ple UV spectrophotometry method for the determination of FF
and FA in pharmaceutical formulations.
The UHPLC method described in present manuscript
allows the lower limit of quantitation of FF in rats’ plasma
down to 100 ng/ml indicating the high sensitivity of the
method. The key achievement of the current study is the devel-
opment of a sensitive simple method based on UHPLC to
quantitate the amount of active metabolite FA in rats’ plasma.
The current developed method is simple, rapid, precise, repro-
ducible and sensitive in addition to other advantages that the
quantitation might be precisely performed with utilizing an
internal standard.
2. Materials and methods
2.1. Chemicals and reagent
Fenoﬁbrate and Fenoﬁbric acid (purity of both = 99.8%)
were purchased from Sigma Aldrich Company St. Louis,
MO, USA. Fluvastatin (IS) was obtained from college of phar-
macy, KSU, Riyadh Saudi Arabia. HPLC grade Methanol was
purchased from BDH laboratory supplies (BDH Chemicals
Ltd., Poole, UK). Rat plasma containing Ethylene Diamine
Tetra Acetic Acid (EDTA) as anticoagulant was collected in-
house which was free from HIV and Hepatitis. The high purity
Milli-Q water was obtained through a Milli-Q Integral Water
Puriﬁcation System (Millipore, Bedford, MA). All other
reagents were of analytical grade and used without further
puriﬁcation.
2.2. UHPLC chromatographic conditions
Chromatographic separation was developed and optimized
with respect to the compositions of stationary and mobile
phase, ﬂow-rate, column temperature, sample volume, and
detection wavelength. The study employed a highly sensitive
UHPLC system that consisted of a Dionex UHPLC binary
solvent manager equipped with a Dionex automatic sample
manager and a Photodiode Array (PDA) ek detector procured
from Thermo scientiﬁc, Bedford, MA, USA. The mobile phase
was an isocratic mixer of HPLC-grade Methanol (MeOH) and
water in a ratio of 65:35%v/v. The ﬂow rate was 0.3 ml/min
delivered through an Acquity UPLC BEH C18 column
(2.1  50 mm, 1.7 lm) kept at 25 C. The total run time was
2.5 min. Freshly prepared mobile phase was ﬁltered throughioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofi-
cokinetics. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.
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online degasser within the UHPLC system. The detector wave-
length was set at 284 nm and the injection volume was 1.0 ll.
2.3. Preparation of stock solution and plasma sample
preparation
Preparation of standard and quality control samples stock
solutions of fenoﬁbrate (FF), fenoﬁbric acid (FA) 1 mg/ml
and ﬂuvastatin (FLV) as the IS were prepared in methanol.
The stock solutions were consecutively diluted with methanol
to prepare working solutions just before use. Plasma FF and
FA standards were prepared by spiking 20 ll of the FF and
FA working standard stock solutions into 180 ll of blank
plasma resulting in plasma FF and FA standard (calibration)
concentrations of 100, 250, 500, 1000, 5000, 10,000 ng/ml. A
ﬁxed amount of IS was added to each sample at a constant
concentration to achieve 2500 ng/ml ﬁnal concentration. Cali-
bration curves were obtained by plotting peak area against
standard drug concentration and regression equations were
computed thereby. Two quality control (QC) samples for each
standard with the selected concentrations LQC 250 ng/ml and
HQC 5000 ng were prepared to cover the desired range.
Liquid–Liquid Extraction (LLE) procedure was used for
the extraction of FF and FA from the rat plasma (Abe
et al., 1998; Masnatta et al., 1996). The drug free plasma sam-
ple was transferred into a series of 1.5 ml centrifugation tubes.
The standard FF and FA solutions with the ﬁxed internal stan-
dard solutions (2500 ng/ml) were added to the plasma sample
and vortexed. Plasma precipitations were carried out using
methanol and vortexed to get the ﬁnal concentration in the
range of 100–10,000 ng/ml. The tubes were centrifuged for
10 min at 2500g. The whole supernatant (organic layer) was
transferred into clean centrifuge tubes and was evaporated to
dryness under nitrogen gas at 45–50 C. Dry residues were
then reconstituted in 200 ll of mobile phase, vortexed and
transferred to an auto sampler vial and injected into the
UHPLC analysis.
2.4. Formulation matrix effect
Direct spectrophotometric analysis of the drug compound may
experience spectral overlapping between the analytes and
excipients used in the dosage form, which signiﬁcantly affects
the method sensitivity, accuracy and precision (Abdel-Hamid
et al., 2012). Therefore, it was required to perform UHPLC
spectral scanning separately for both drug-containing and
drug-free formulations of liquid to detect any possible interfer-
ence. In the present study, the FF and FA were loaded in self
emulsifying lipid based formulation from lower to higher con-
centrations in order to test the extent of the matrix effect. The
internal standard FLV was loaded at a constant concentration
in the formulation to justify the maximum possible recovery.
2.5. Method validation
The current developed method was validated according to
ICH guidelines in terms of linearity, speciﬁcity, precision and
accuracy, Limit of Detection (LOD) and Lower Limit of
Quantiﬁcation (LLOQ) according to the standard guidelines
of bioanalytical method validation (Matuszewski, 2006).Please cite this article in press as: Alamri, R.G. et al. Development and validation of b
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nes [29–30] in rat plasma in order to evaluate the method for
selectivity, linearity of response, accuracy, precision, recovery,
limit of detection and quantiﬁcation and robustness.
2.5.1. Linearity and calibration
Appropriate volumes of FF and FA stock solutions (1 mg/ml)
were utilized to prepare six non-zero standard drug concentra-
tions covering the calibration range of 100–10,000 ng/ml. Two
QC samples (LQC and HQC) were prepared by spiking known
concentrations of FF and FA within the detection range of
100–10,000 ng/ml. Each standard solution 100, 250, 500,
1000, 5000, 10,000 ng/ml has been injected n= 3 times daily
on three consecutive days for validation. Calibration solutions
were injected in ascending order in each validation run and the
other samples were distributed randomly through the run. Lin-
ear regression equation and correlation coefﬁcient (R2) were
employed to statistically evaluate the linearity of the results,
y= mx+ b, where; y= response, m= slope, x= concentra-
tion, b= intercept.
2.5.2. Accuracy, precision and recovery
From the six FF and FA standards solutions, intra-day accu-
racy and precision studies were performed by using six repli-
cates determinations within the same day. On the other
hand, the inter-day accuracy and precision were also assessed
by six replicates analysis during the three consecutive days of
the following: low and high QC samples. The overall precision
of the method was expressed as relative standard deviation
(SD) as the following equation: The extraction recovery of
the FF and FA from plasma and solution samples was carried
out at two concentration levels lower QC (LQC= 250 ng/ml)
and high QC (HQC= 5000 ng/ml) by analysis of replicate
(n= 6) samples. The peak areas obtained for plasma QC sam-
ples were compared with those of analytical standards to cal-
culate the recovery of FF and FA.
2.5.3. Limit of Detection (LOD) and Lower Limit of
Quantification (LLOQ)
The LOD and LLOQ were determined efﬁciently by serial
dilutions of the FF and FA stock solutions in order to obtain
signal to noise (S/N) ratio of at least 3:1 for LOD and 10:1
for LLOQ.
2.5.4. Specificity and selectivity
Speciﬁcity and sensitivity of the method were evaluated in rela-
tion to observe any interference peaks from the different self-
emulsifying lipid-based formulations and importantly from
the endogenous plasma constitutes. Six individual drug free
lipid formulations and blank plasma samples were compared
with those obtained by spiking FF and metabolite FA and
IS into the corresponding blank plasma sample to screen
plasma interference. Calibration curves were generated with
peak area ratios of the analytes to IS vs. concentration.2.5.5. Robustness
The effects on the analytical results were examined by the
robustness of the present method, which was evaluated with
deliberate changes in the mobile phase composition. Different
concentrations of methanol and water as mobile phases wereioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofi-
okinetics. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.
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% RSD of peak area was calculated (Mennickent et al., 2009).
2.5.6. Stability
The short term stability of standard and sample solutions of
FF and FA was carried out by assaying the drug after 24
and 48 h at room temperature and 20 C against fresh stan-
dard solutions. Long-term stability was evaluated after storing
samples at 80 C for 30 days. All stability experiments were
carried out against freshly spiked calibration standards.
2.6. Application to pharmacokinetic study
Healthy male Wistar rats (150–200 g) were used for the study.
Animals were issued from Central Animal House Facility of
King Saud University and were kept in standard plastic animal
cage in groups of 6 animals with 12 h light and dark cycle at
25 ± 2 C. The rats were fed on standard rat chow and pro-
vided water ad libitum. The animals were acclimatized to lab-
oratory conditions for a week prior to experiments. The FA
dissolved in 1% CMC-Na and administered to the rats by oral
gavage (9 mg/kg). Blood samples were withdrawn from the
post ocular ophthalmic vein at 0.0, 0.5, 1.0, 1.5, 3.0, 4.5, 6.0,
12.0, 24.0 and 36.0 h after oral administration. Plasma was
separated from each sample by centrifugation at 2500g for
10 min and frozen at 20 C until analysis.
The pharmacokinetic analysis was performed using PK Sol-
ver software (version 1.0). The parameters calculated were as
follows: area under plasma concentration–time curve (AUC)
using linear trapezoid method; volume of distribution (Vd
area), where Vd area = (dose/AUC  b); and absorption rate
constant (Ka), where ka = (1/MAT). The elimination rate
constant (Ke) was calculated from the slope of the logarithm
of the plasma concentration versus time. The apparent elimi-
nation half-life (T1/2) was calculated as 0.693/Ke. The maxi-
mum plasma concentration (Cmax) and time to maximum
concentration (Tmax) after p.o administration were determined
empirically directly from the time–concentration curve.
Results are expressed as mean values ± SEM.
2.7. Statistical analysis
The data were expressed as mean ± standard error of mean
(SEM). The signiﬁcance was determined by applying one-
way ANOVA. P values <0.05 were considered signiﬁcant.3. Results and discussion
3.1. Optimization of UHPLC conditions
The representative chromatographic results of blank plasma
sample (Fig. 2A), drug free self-emulsifying lipid formulation
sample (Fig. 2B), FA standard solution 1000 ng/ml (Fig. 2C)
FA with IS sample (Fig. 2D), and FA and FF containing
self-emulsifying lipid formulation (QC2) sample (Fig. 2E) are
shown in Fig. 2. The chromatographic results found from
the current UHPLC technique showed that the FA and FF
peaks were well separated in the plasma sample and ideal with-
out any interference of the excipients used in liquid dosage
form. In addition, the chromatograms in the assay conﬁrmedPlease cite this article in press as: Alamri, R.G. et al. Development and validation of b
brate and its metabolite fenofibric acid in rat plasma: Application to pharma
jsps.2016.05.008that the sensitivity and selectivity of this procedure is efﬁcient
enough to determine FF within the available excipients for
dosage forms. The FA analyte was well separated at the reten-
tion time of 0.72 min without having any interference of
degradation product. The total run time was 2.5 min, where
the peaks were of good shape and completely resolved.
3.2. Matrix effect of the formulation
The assessments of matrix effect represented an integral part of
validation procedure for quantitative analysis of drug in any
dosage forms within this analytical method development
(Gao et al., 2011; Matuszewski et al., 2003). The matrix effects
were investigated at two different concentration levels of FF
and FA along with constant internal standard in self-
emulsifying lipid based formulation. In the present analysis,
the total FA recovery (>95%) and the overall process efﬁ-
ciency demonstrated that the proposed method was practically
free from relative matrix effects for the determination of FF
and FA in liquid dosage forms using lipid based formulation.
3.3. Method validation
3.3.1. Linearity and calibration
The peak responses of both FF andFAwere linear over the con-
centration range between 100 and 10,000 ng/ml. Under the
above described experimental conditions, the calibration curve
of chromatographic peak area versusFFandFAconcentrations
have shown good linear dynamic range. These results showed an
excellent linear method over the interval studied with correla-
tion coefﬁcient, FF (r2) = 0.9996 and FA (r2) = 0.9993. Slope,
intercept, correlation coefﬁcient (r2), standard deviation of slope
and intercept (obtained by the linear least squares treatment of
the results) are listed in Table 1. The LOD and LOQ of the
method were found to be 30 and 90 ng ml1 for FF and 40
and 100 ng ml1 for FA, respectively.
3.3.2. Accuracy, precision and recovery
The intra-day and inter-day accuracy studies were calculated
as the percentage of drug recovery after examining six repli-
cates of QC samples at two nominal concentration levels
(250 and 5000 ng/ml). The data show that the intra-day accu-
racy was found in between 96.00% and 100.00% and the inter-
day accuracy was in between 96.39% and 100.00% (Table 2).
The overall results from the drug recovery suggest the accuracy
of the assay method, which meet all the criteria as per the ICH
guidelines (Q2A, 2005).
The values present in Table 2 showed the results of intra-day
and inter-day precision, respectively. The standard deviation
(SD) values from the intra-day results are within the acceptable
range, which indicates that the developed method was precise.
In addition, within the analytical concentration range of
100–10,000 ng/ml, the coefﬁcient of variation (CV; precision)
was found to be within 1.50–4.20%. The inter-day (Table 2)
SD values of six replicate determinations in three consecutive
days were within the acceptable range, whereas the % CV was
in between the range of 0.86% and 4.01%. These low values
of both SD and CV during the intra-day and inter-day analysis
suggest the current method as highly precised.
Extraction recovery of FF and FA was determined by com-
paring the peak areas from the extracted QC samples withioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofi-
cokinetics. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.
Figure 2 UHPLC chromatograms of blank plasma sample (A), drug free self-emulsifying lipid formulation sample (B), FA standard
solution 1000 ng/ml (C), FA with FLV (internal standard) sample (D), and FF and FA containing self-emulsifying lipid formulation
(QC2) sample (E).
Development and validation of bioanalytical UHPLC-UV method 5unextracted standards that represent 100% recovery. LQC and
HQC samples relative and absolute recovery were found to be
101.30%, 102.33%, and 89.32%, 91.29% for FF and 100.55%,
101.30%, and 90.58%, 89.65% for FA, respectively (Table 3).
3.3.3. Limit of Detection (LOD) and Lower Limit of
Quantification (LLOQ)
The LOQ in the assay was 100 ng/ml which estimated to be the
lowest concentration in the standard curve that can be
measured with acceptable accuracy and precision for the FF
and FA according to ICH recommendations (Q2A, 2005)Please cite this article in press as: Alamri, R.G. et al. Development and validation of b
brate and its metabolite fenofibric acid in rat plasma: Application to pharmac
jsps.2016.05.008and with S/N ratio of (65.13). On the other hand, LOD was
30 ng/ml for FF and 40 ng/ml for FA with S/N ratio of
13.17 and 13.18 respectively.
3.3.4. Specificity
The speciﬁcity of the developed UHPLC method for FF and
FA was studied in order to achieve an indication of the possi-
ble interferences from the degradation product(s) if present.
The result in Fig. 2B shows that there were no degradation
products present in the FF and FA sample (% drug recov-
ered). It suggests that FF and FA compounds can be recoveredioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofi-
okinetics. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.
Table 1 Statistical regression data for the determination of
FF and FA obtained from the proposed method.
Parameters UHPLC analysis
FF FA
Concentration range (ng/ml) 100–10,000 100–10,000
Intercept (a) 0.1278 0.1519
Slope (b) 0.3318 1.7451
Correlation coeﬃcient (r) 0.9996 0.9993
Standard deviation of Intercept (Sa)a 0.011 0.053
Standard deviation of Slope (Sb)a 0.013 0.098
Limit of Detection (LOD)b 0.03 0.04
Lower Limit of Quantiﬁcation
(LLOQ)c
0.09 0.10
a Mean of three measurements.
b Limit of detection was estimated at a signal-to-noise ratio of 3.
c Limit of quantiﬁcation was estimated at a signal-to-noise ratio
of 10.
6 R.G. Alamri et al.completely from the lipid formulation. Consequently, the R
value in this assay can be calculated based on the availability
of FF and FA peak only. In addition, there were no signiﬁcant
interfering peaks present at the same FF and FA retention
time in the randomly selected QC samples (drug free liquid/
solid self-emulsifying lipid formulation (QCzero) samples,
Fig. 2C). Thus the analysis indicated that FF and FA can be
detected without any loss/or missing from lipid based
formulations.Table 2 Evaluation of accuracy and precision of the proposed m
Inter-day and intra-day assay.
Assay type Amount (ng/ml)
Added Found ± SD
Inter day 250 258.66 ± 12.05
5000 5186 ± 268.74
Intra day 250 253 ± 7.54
5000 5062.32 ± 788.83
Inter day 250 249.45 ± 4.72
5000 5065 ± 175.81
Intra day 250 251.43 ± 7.16
5000 5090.26 ± 226.30
Table 3 Analytical relative/absolute recovery of FF and FA in rat
Added conc. (ng/ml) (n= 6) FF
Measured conc. (ng/ml) Relative r
250 252.66 ± 4.16 101.30
CV% 1.64 –
5000 5113.51 ± 106.85 102.33
CV% 2.08 –
Extraction recovery in
Solution (%)
Absolute recovery (250 lg/ml, n= 6) 103.69
Absolute recovery (5000 lg/ml, n= 6) 104.25
Please cite this article in press as: Alamri, R.G. et al. Development and validation of b
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The values of % RSD obtained for FF (0.024–1.06%) and FA
(0.028–0.93%) after small changes in mobile phase composi-
tions (methanol: water 62:38 v/v and 67:33 v/v) indicated the
method was robust. There was no signiﬁcant variation in slope
values (P > 0.05).
3.3.6. System suitability
The system suitability was considered to estimate/settle the
performance (parameters) and the highest precision of the sys-
tems. The variation (SD) in the peak area from six replicates
injections was very minor, which demonstrates the system pre-
cision. The results of other chromatographic parameters such
as peak tailing and theoretical plate numbers representing col-
umn efﬁciency are represented in Table 4. The overall analysis
of the results shows the acceptable/highest performance of the
system as the tailing peaks were 1.38 and 1.48 for both FF and
FA, respectively along with the theoretical plates, which were
not less than 2000.
3.3.7. Stability
The freeze and thaw stability of FF and FA was determined
after three freeze and thaw cycles each lasting 24 h. Quality
control samples were extracted and analyzed after the third
cycle (two levels in duplicate), and results were compared to
the theoretical (spiked) values. The short-term stability was
validated for 6 h and post-preparative stability was validatedethod for the simultaneous determination of FF and FA, by
Precision Accuracy (%) Drug response
4.20 104.20 FF
2.16 105.36
1.50 97.15
2.90 99.48
0.86 97.37 FA
4.01 99.12
2.63 101.85
3.16 100.15
plasma.
FA
ecovery (%) Measured conc. (ng/ml) Relative recovery (%)
254.60 ± 4.33 100.55
1.70 –
5167 ± 138.84 101.30
2.68 –
plasma vs. solution
Plasma (%) Solution (%) Plasma (%)
89.32 101.69 90.58
91.29 103.27 89.65
ioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofi-
cokinetics. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.
Table 4 Systems suitability parameters of FF and FA.
System suitability parameter Drug response
FF FA
Retention time (min) 1.13 0.72
Peak tailing 1.48 1.38
Theoretical plate number 3845 4132
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Figure 3 Plasma concentration–time proﬁles of fenoﬁbric acid
after a single oral administration of fenoﬁbrate loaded formula-
tion to male Wistar rats at a dose equivalent to 9 mg/kg
fenoﬁbrate (mean ± SEM, n= 6).
Table 5 Pharmacokinetic parameters of fenoﬁbric acid in
male Wistar rats.
Pharmacokinetic parameters Mean ± SD
Cmax (ng/ml) 549.39 ± 29.73
Tmax (h) 6 ± 0
AUC0–t (ng h/ml) 7329.50 ± 191.40
AUC0–1 (ng h/ml) 15059.55 ± 527.12
AUMC0–t (ng h/ml) 99970.36 ± 3035.27
AUMC0–1 (ng h/ml) 932758.9 ± 351338.2
T1/2k (h) 25.69 ± 1.23
Development and validation of bioanalytical UHPLC-UV method 7for 48 h, both at room temperature. Long-term stability was
assessed after storage of the test samples at 80 C for 30 days.
All stability experiments were carried out against freshly
spiked calibration standards. Results of the stability experi-
ments were always well within ±15% of deviation, and it
shows that no degradation of FF and FA occurred under
the described conditions.
4. Method application: pharmacokinetic studies
The validated UHPLC method was successfully applied to a
pharmacokinetic study of the active metabolite fenoﬁbric acid
in male Wistar rats. Fig. 3 shows the mean plasma concentra-
tion–time curve of fenoﬁbric acid in single dose study is shown
in Fig. 3. After administration of a single dose of 9 mg/kg
fenoﬁbric acid orally, the pharmacokinetics parameters forPlease cite this article in press as: Alamri, R.G. et al. Development and validation of b
brate and its metabolite fenofibric acid in rat plasma: Application to pharmac
jsps.2016.05.008FA are shown in Table 5. The mean maximum plasma concen-
tration (Cmax) was 549.39 ng/ml, and the time to reach maxi-
mum concentration (Tmax) was 6 h. The half-life (T1/2) was
29.33 h and the AUC0–t was 7329.50 ng h/ml. These parame-
ters were in accordance with those reported in the literature
(Li et al., 2009; Miller and Spence, 1998; Wang et al., 2012).5. Conclusion
The developed UHPLC method provides a reliable, repro-
ducible and more speciﬁc assay for FF and FA analysis in
plasma and pharmaceutical formulations. The described
method is sensitive enough to detect as low as 30 ng/ml (FF)
and 40 ng/ml (FA) and exclusively offers a rapid determination
of FF and FA (peak at 1.13 and 0.72 min within 2.5 min run
time). No signiﬁcant interferences were caused by the formula-
tion excipients, diluents and/or degradation products. The val-
idation method allows quantiﬁcation of FF and FA in pure
and pharmaceutical formulations in the range between 100
and 10,000 ng/ml. Compared to previously reported methods,
the present assay method assessed extensive validation param-
eters as per ICH guidelines. The method has shown acceptable
precision, accuracy and adequate sensitivity and demands to
be in use for further human studies. The established method
satisﬁes the system suitability criteria, peak integrity, and res-
olution of the drug peak. The overall results clearly indicate
that the current method is attractive due to the good selectivity
for quantitative determination of FF and FA in self-
emulsifying lipid-based formulation and also suitable for
in vivo animal studies.
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